Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/BCR_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/BCR_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BCR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/BCR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/BCR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/BCR_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0034329 | Colorectum | AD | cell junction assembly | 136/3918 | 420/18723 | 2.02e-08 | 1.15e-06 | 136 |
GO:0150115 | Colorectum | AD | cell-substrate junction organization | 44/3918 | 101/18723 | 2.38e-07 | 9.81e-06 | 44 |
GO:0031589 | Colorectum | AD | cell-substrate adhesion | 116/3918 | 363/18723 | 4.68e-07 | 1.76e-05 | 116 |
GO:0007044 | Colorectum | AD | cell-substrate junction assembly | 41/3918 | 95/18723 | 8.20e-07 | 2.85e-05 | 41 |
GO:0043087 | Colorectum | AD | regulation of GTPase activity | 110/3918 | 348/18723 | 1.64e-06 | 5.03e-05 | 110 |
GO:0007265 | Colorectum | AD | Ras protein signal transduction | 104/3918 | 337/18723 | 1.01e-05 | 2.35e-04 | 104 |
GO:0051056 | Colorectum | AD | regulation of small GTPase mediated signal transduction | 94/3918 | 302/18723 | 1.81e-05 | 3.76e-04 | 94 |
GO:0046777 | Colorectum | AD | protein autophosphorylation | 74/3918 | 227/18723 | 2.48e-05 | 4.76e-04 | 74 |
GO:0007160 | Colorectum | AD | cell-matrix adhesion | 75/3918 | 233/18723 | 3.56e-05 | 6.45e-04 | 75 |
GO:0048041 | Colorectum | AD | focal adhesion assembly | 34/3918 | 87/18723 | 8.30e-05 | 1.30e-03 | 34 |
GO:0043547 | Colorectum | AD | positive regulation of GTPase activity | 75/3918 | 255/18723 | 7.95e-04 | 7.91e-03 | 75 |
GO:0046578 | Colorectum | AD | regulation of Ras protein signal transduction | 56/3918 | 189/18723 | 2.85e-03 | 2.14e-02 | 56 |
GO:0007266 | Colorectum | AD | Rho protein signal transduction | 42/3918 | 137/18723 | 4.64e-03 | 3.16e-02 | 42 |
GO:0009913 | Colorectum | AD | epidermal cell differentiation | 58/3918 | 202/18723 | 5.16e-03 | 3.42e-02 | 58 |
GO:0008544 | Colorectum | AD | epidermis development | 87/3918 | 324/18723 | 5.99e-03 | 3.76e-02 | 87 |
GO:00343291 | Colorectum | SER | cell junction assembly | 100/2897 | 420/18723 | 4.23e-06 | 1.61e-04 | 100 |
GO:01501151 | Colorectum | SER | cell-substrate junction organization | 34/2897 | 101/18723 | 4.46e-06 | 1.67e-04 | 34 |
GO:00467771 | Colorectum | SER | protein autophosphorylation | 60/2897 | 227/18723 | 1.36e-05 | 4.25e-04 | 60 |
GO:00070441 | Colorectum | SER | cell-substrate junction assembly | 31/2897 | 95/18723 | 2.34e-05 | 6.64e-04 | 31 |
GO:00315891 | Colorectum | SER | cell-substrate adhesion | 86/2897 | 363/18723 | 2.36e-05 | 6.64e-04 | 86 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BCR | SNV | Missense_Mutation | | c.900G>C | p.Gln300His | p.Q300H | P11274 | protein_coding | tolerated_low_confidence(0.47) | benign(0.275) | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BCR | SNV | Missense_Mutation | | c.2311N>C | p.Glu771Gln | p.E771Q | P11274 | protein_coding | deleterious(0.04) | possibly_damaging(0.688) | TCGA-BH-A209-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BCR | SNV | Missense_Mutation | novel | c.3671N>C | p.Asn1224Thr | p.N1224T | P11274 | protein_coding | tolerated(0.15) | benign(0.001) | TCGA-D8-A1JU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
BCR | SNV | Missense_Mutation | | c.2710N>A | p.Asp904Asn | p.D904N | P11274 | protein_coding | deleterious(0.03) | benign(0.41) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
BCR | insertion | In_Frame_Ins | novel | c.2067_2068insTTAGTACCAGGAATTAATCTCAGCTCCTTCCCA | p.Asn689_Glu690insLeuValProGlyIleAsnLeuSerSerPhePro | p.N689_E690insLVPGINLSSFP | P11274 | protein_coding | | | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
BCR | deletion | Frame_Shift_Del | novel | c.2203delC | p.Leu735PhefsTer53 | p.L735Ffs*53 | P11274 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
BCR | SNV | Missense_Mutation | rs775101020 | c.1607N>T | p.Pro536Leu | p.P536L | P11274 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
BCR | SNV | Missense_Mutation | novel | c.3656N>A | p.Ser1219Asn | p.S1219N | P11274 | protein_coding | deleterious(0.03) | benign(0.104) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
BCR | SNV | Missense_Mutation | | c.1816N>C | p.Glu606Gln | p.E606Q | P11274 | protein_coding | tolerated(0.1) | benign(0.217) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
BCR | SNV | Missense_Mutation | | c.1816N>C | p.Glu606Gln | p.E606Q | P11274 | protein_coding | tolerated(0.1) | benign(0.217) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
613 | BCR | TUMOR SUPPRESSOR, SERINE THREONINE KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, KINASE, ENZYME, DRUGGABLE GENOME | | Vincristine | VINCRISTINE | |
613 | BCR | TUMOR SUPPRESSOR, SERINE THREONINE KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, KINASE, ENZYME, DRUGGABLE GENOME | | Omacetaxine | | |
613 | BCR | TUMOR SUPPRESSOR, SERINE THREONINE KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, KINASE, ENZYME, DRUGGABLE GENOME | | imatinib | IMATINIB | |
613 | BCR | TUMOR SUPPRESSOR, SERINE THREONINE KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, KINASE, ENZYME, DRUGGABLE GENOME | | bosutinib | BOSUTINIB | |
613 | BCR | TUMOR SUPPRESSOR, SERINE THREONINE KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | SARACATINIB | SARACATINIB | |
613 | BCR | TUMOR SUPPRESSOR, SERINE THREONINE KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, KINASE, ENZYME, DRUGGABLE GENOME | | Inotuzumab Ozogamicin | | |
613 | BCR | TUMOR SUPPRESSOR, SERINE THREONINE KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, KINASE, ENZYME, DRUGGABLE GENOME | | homoharringtonine | OMACETAXINE MEPESUCCINATE | |
613 | BCR | TUMOR SUPPRESSOR, SERINE THREONINE KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE, KINASE, ENZYME, DRUGGABLE GENOME | | Busulfan | BUSULFAN | |